Discovery of a metabolic alternative to the classical mevalonate pathway
Nikki Dellas,
Suzanne T Thomas,
Gerard Manning,
Joseph P Noel
Affiliations
Nikki Dellas
Howard Hughes Medical Institute, Salk Institute for Biological Studies, La Jolla, United States; Jack H Skirball Center for Chemical Biology and Proteomics, Salk Institute for Biological Studies, La Jolla, United States; Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, United States
Suzanne T Thomas
Jack H Skirball Center for Chemical Biology and Proteomics, Salk Institute for Biological Studies, La Jolla, United States
Gerard Manning
Razavi Newman Center for Bioinformatics, Salk Institute for Biological Studies, La Jolla, United States
Joseph P Noel
Howard Hughes Medical Institute, Salk Institute for Biological Studies, La Jolla, United States; Jack H Skirball Center for Chemical Biology and Proteomics, Salk Institute for Biological Studies, La Jolla, United States
Eukarya, Archaea, and some Bacteria encode all or part of the essential mevalonate (MVA) metabolic pathway clinically modulated using statins. Curiously, two components of the MVA pathway are often absent from archaeal genomes. The search for these missing elements led to the discovery of isopentenyl phosphate kinase (IPK), one of two activities necessary to furnish the universal five-carbon isoprenoid building block, isopentenyl diphosphate (IPP). Unexpectedly, we now report functional IPKs also exist in Bacteria and Eukarya. Furthermore, amongst a subset of species within the bacterial phylum Chloroflexi, we identified a new enzyme catalyzing the missing decarboxylative step of the putative alternative MVA pathway. These results demonstrate, for the first time, a functioning alternative MVA pathway. Key to this pathway is the catalytic actions of a newly uncovered enzyme, mevalonate phosphate decarboxylase (MPD) and IPK. Together, these two discoveries suggest that unforeseen variation in isoprenoid metabolism may be widespread in nature.